Genocea Biosciences, Inc. (NASDAQ:GNCA) shares were down 4.2% during mid-day trading on Thursday . The stock traded as low as $1.41 and last traded at $1.37. Approximately 444,342 shares traded hands during mid-day trading, a decline of 64% from the average daily volume of 1,248,810 shares. The stock had previously closed at $1.43.

Several research analysts have issued reports on GNCA shares. Needham & Company LLC upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research report on Monday, July 24th. Cowen and Company reiterated a “buy” rating and issued a $10.00 price objective on shares of Genocea Biosciences in a research report on Tuesday, September 26th. Zacks Investment Research upgraded Genocea Biosciences from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Monday. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Finally, Stifel Nicolaus cut Genocea Biosciences from a “buy” rating to a “hold” rating and cut their price objective for the stock from $15.00 to $2.50 in a research report on Monday, September 25th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Genocea Biosciences has a consensus rating of “Buy” and a consensus target price of $9.48.

The firm’s 50-day moving average price is $3.43 and its 200 day moving average price is $5.03. The stock’s market capitalization is $40.07 million.

Genocea Biosciences (NASDAQ:GNCA) last announced its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.08). On average, equities analysts forecast that Genocea Biosciences, Inc. will post ($1.92) EPS for the current year.

In other news, CFO Jonathan Poole sold 45,000 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $6.00, for a total value of $270,000.00. Following the completion of the sale, the chief financial officer now owns 84,247 shares in the company, valued at $505,482. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 6.70% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System acquired a new stake in shares of Genocea Biosciences in the second quarter valued at $265,000. State Street Corp lifted its holdings in shares of Genocea Biosciences by 1,595.2% in the second quarter. State Street Corp now owns 366,172 shares of the biotechnology company’s stock valued at $1,912,000 after buying an additional 344,572 shares during the period. OxFORD Asset Management LLP acquired a new stake in shares of Genocea Biosciences in the second quarter valued at $204,000. Vanguard Group Inc. lifted its holdings in shares of Genocea Biosciences by 13.9% in the second quarter. Vanguard Group Inc. now owns 856,762 shares of the biotechnology company’s stock valued at $4,472,000 after buying an additional 104,790 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Genocea Biosciences by 642.9% in the second quarter. Northern Trust Corp now owns 306,597 shares of the biotechnology company’s stock valued at $1,601,000 after buying an additional 265,328 shares during the period. Institutional investors and hedge funds own 59.25% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Genocea Biosciences, Inc. (GNCA) Shares Down 4.2%” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/genocea-biosciences-inc-gnca-shares-down-4-2/1641799.html.

About Genocea Biosciences

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.